TDO2 and prostate carcinoma: However, although Cort108297 alone or in combination with the AhR inhibitor CH223191 significantly inhibited cell growth in LNCaP-EnzR cells (Supplementary Fig. S20b), Cort108297 was not as effective in blocking the TDO2-AhR pathway as it was in LNCaP cells (Supplementary Figs. S19a–c and S20a), suggesting that targeting GR was more effective in ADT-treated androgen-sensitive prostate cancer cells than in recurrent late-stage prostate cancer cells.